Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
65
CTKB Quote, Financials, Valuation and Earnings
Last price:
$5.02
Seasonality move
:
13.97%
Day range:
$4.95 - $5.19
52-week range:
$2.37 - $7.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.32x
P/B ratio:
1.72x
Volume:
1.2M
Avg. volume:
1.8M
1-year change:
-19.3%
Market cap:
$652.1M
Revenue:
$200.5M
EPS (TTM):
-$0.10
Analysts' Opinion
-
Consensus RatingCytek Biosciences, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.75, Cytek Biosciences, Inc. has an estimated upside of 12.75% from its current price of $5.10.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $5.10.
Fair Value
-
According to the consensus of 4 analysts, Cytek Biosciences, Inc. has 12.75% upside to fair value with a price target of $5.75 per share.
CTKB vs. S&P 500
-
Over the past 5 trading days, Cytek Biosciences, Inc. has overperformed the S&P 500 by 7.4% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cytek Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cytek Biosciences, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Cytek Biosciences, Inc. reported revenues of $52.3M.
Earnings Growth
-
Cytek Biosciences, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Cytek Biosciences, Inc. reported earnings per share of -$0.04.
Enterprise value:
425.5M
EV / Invested capital:
1.03x
Price / LTM sales:
3.32x
EV / EBIT:
--
EV / Revenue:
2.16x
PEG ratio (5yr expected):
-1.63x
EV / Free cash flow:
-71.18x
Price / Operating cash flow:
54.40x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$105.2M
Return On Assets:
-2.6%
Net Income Margin (TTM):
-6.51%
Return On Equity:
-3.34%
Return On Invested Capital:
-3.09%
Operating Margin:
-17.58%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $183.1M | $201.2M | $196.8M | $51.5M | $52.3M | |
| Gross Profit | $106.4M | $110.5M | $105.2M | $29M | $27.6M | |
| Operating Income | -$25.5M | -$23.6M | -$34.4M | -$4.2M | -$9.2M | |
| EBITDA | -$18.4M | -$13.5M | -$22.8M | -$1.4M | -$6.1M | |
| Diluted EPS | -$0.10 | -$0.08 | -$0.10 | $0.01 | -$0.04 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $439.8M | $443.9M | $422.3M | $390.2M | $388.5M | |
| Total Assets | $454.3M | $499.3M | $519.4M | $491.2M | $494.9M | |
| Current Liabilities | $30M | $41.5M | $58.7M | $62.8M | $75.2M | |
| Total Liabilities | $51.1M | $82.8M | $103.9M | $105.8M | $116.3M | |
| Total Equity | $403.2M | $416.5M | $415.5M | $385.5M | $378.6M | |
| Total Debt | -- | $31.6M | $15M | $30.6M | $32.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2M | $32.9M | -$1.9M | $13.2M | -$3.9M | |
| Cash From Investing | -$174M | $9.5M | -$51.5M | -$15.8M | $18.9M | |
| Cash From Financing | -$4.2M | -$45.9M | -$15.8M | -$12.1M | $1.9M | |
| Free Cash Flow | -$7.9M | $28.5M | -$6M | $12.2M | -$4.6M | |
CTKB
Sector
Market Cap
$652.1M
$28.4M
Price % of 52-Week High
69.86%
51.17%
Dividend Yield
0%
0%
Shareholder Yield
4.49%
-1.49%
1-Year Price Total Return
-19.3%
-16.67%
Beta (5-Year)
--
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$4.85
200-day SMA
Buy
Level
$3.90
Bollinger Bands (100)
Buy
Level
3.7 - 4.92
Chaikin Money Flow
Buy
Level
11.7M
20-day SMA
Sell
Level
$5.13
Relative Strength Index (RSI14)
Buy
Level
54.62
ADX Line
Buy
Level
19.71
Williams %R
Neutral
Level
-42.5532
50-day SMA
Buy
Level
$4.72
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
54.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.6661)
Buy
CA Score
(Annual)
Level (0.8102)
Buy
Beneish M-Score
(Annual)
Level (-2.6922)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-1.2418)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in 1992 and is headquartered in Fremont, CA.
Stock Forecast FAQ
In the current month, CTKB has received 1 Buy ratings 3 Hold ratings, and 0 Sell ratings. The CTKB average analyst price target in the past 3 months is $5.75.
-
Where Will Cytek Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cytek Biosciences, Inc. share price will rise to $5.75 per share over the next 12 months.
-
What Do Analysts Say About Cytek Biosciences, Inc.?
Analysts are divided on their view about Cytek Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cytek Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Cytek Biosciences, Inc.'s Price Target?
The price target for Cytek Biosciences, Inc. over the next 1-year time period is forecast to be $5.75 according to 4 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is CTKB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cytek Biosciences, Inc. is a Hold. 3 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CTKB?
You can purchase shares of Cytek Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cytek Biosciences, Inc. shares.
-
What Is The Cytek Biosciences, Inc. Share Price Today?
Cytek Biosciences, Inc. was last trading at $5.02 per share. This represents the most recent stock quote for Cytek Biosciences, Inc.. Yesterday, Cytek Biosciences, Inc. closed at $5.10 per share.
-
How To Buy Cytek Biosciences, Inc. Stock Online?
In order to purchase Cytek Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CTKB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CTKB
Sector
P/E ratio
--
23.89x
PEG ratio
-1.63x
-0.01x
P/B ratio
1.72x
1.81x
Price / LTM sales
3.32x
1.58x
Growth Metrics
CTKB
Sector
Revenue growth
1.54%
4.62%
Earnings growth
-705.63%
10.7%
Revenue (5-year growth)
28.2%
6.5%
Earnings forecast
$0.01
-$0.21
Profitability
CTKB
Sector
Profitability FY 2024
$111.1M
$3.6M
Return on invested capital
-3.09%
-31.84%
Return on assets
-2.6%
-27.96%
Return on equity
-3.34%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
4
Balance Sheet
CTKB
Sector
Total cash
$261.7M
$26.4M
Short term investments
$179.1M
$25.7M
Total assets
$502.1M
$76.9M
Long term debt
$32.1M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 4.05% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is up 0.41% over the past day.
Buy
60
ZBIO alert for Dec 23
Zenas BioPharma, Inc. [ZBIO] is up 1.02% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
